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In a recent paper published online in Molecular Psychiatry, Skaﬁdas
et al.
1 report a classiﬁer for identifying individuals at risk for autism
spectrum disorders (ASDs). Their classiﬁer is based on 267 single-
nucleotide polymorphisms (SNPs) that were selected from the
results of a pathway analysis using cases from the Autism Genetic
Resource Exchange (AGRE).
1 Using within-sample cross-validation,
the authors claim a classiﬁcation accuracy for ASDs of 85.6%. They
subsequently applied their classiﬁer to ASD cases from the Simons
Foundation Autism Research Initiative (SFARI) and controls from
the Wellcome Trust Birth Cohort (WTBC) and report ASD
classiﬁcation accuracy of 71.7%.
We believe that the claims made by Skaﬁdas et al.
1 are
inconsistent with current knowledge of the genetics of ASDs,
2 and
inconsistent with the expected precision of risk predictions for
complex psychiatric disorders. Further, as classiﬁcation accuracy
depends on the size of the discovery sample, the results are also
inconsistent with the size of the sample they employed (only 123
controls were included in the discovery set).
To examine the validity of Skaﬁdas et al.’s claims, we pursued a
range of analyses to assess the evidence for association between
ASDs and (1) the individual SNPs named in their paper as most
predictive, (2) their genetic classiﬁer, to the extent it was described
and (3) the pathways identiﬁed in the report, from which the
predictive SNPs were selected. For each analysis, where possible,
we attempted to replicate the analytic approach of Skaﬁdas et al.
1
using data from the Psychiatric Genomics Consortium (PGC)
autism group, which includes ∼5400 cases, more than three times
the number used in the original report. The methodology of these
analyses is described in detail in Supplementary Information.
First, we found no evidence for single SNP associations between
any of the 30 most contributory SNPs listed by Skaﬁdas et al.
1 in
their Table 2 and ASDs in the PGC (Table 1). In the current PGC
meta-analysis, the mean P-value for these SNPs was 0.47 with a
minimum 0.007, and none are notable or survive a 30 SNP
correction for multiple testing. Further information on these
associations can be found in Supplementary Information.
Table 1. Meta-analytic results for the 30 most predictive SNPs in the
Skaﬁdas classiﬁer
SNP Chr BP A1 A2 ln(OR) P-value
rs260808 11 103909166 A C −0.024 0.510
rs769052 5 138944433 T C −0.042 0.422
rs876619 16 56283534 A C 0.044 0.398
rs905646 11 88353802 A G 0.062 0.167
rs968122 12 70791615 T C 0.001 0.974
rs984371 11 55577698 T C 0.018 0.594
rs1243679 14 21093733 A G 0.027 0.710
rs1818106 11 103913376 A C 0.009 0.736
rs2239118 12 2660753 T C 0.054 0.097
rs2240228 19 15852872 A G 0.083 0.007
rs2300497 14 90865283 T C 0.034 0.408
rs2384061 2 25135620 A G 0.052 0.058
rs3773540 3 55096928 A G −0.085 0.273
rs4128941 17 63531331 A G −0.123 0.085
rs4308342 4 71884205 T G −0.107 0.142
rs4648135 4 103536670 A G 0.008 0.894
rs6483362 11 88412451 A G −0.0335 0.513
rs7313997 12 71265958 A C 0.035 0.450
rs7562445 2 213192048 T G 0.042 0.279
rs7842798 8 131890170 A G 0.033 0.241
rs8053370 16 56262906 T C −0.042 0.415
rs9288685 2 233987114 T C −0.007 0.804
rs10193128 2 233987722 T C −0.015 0.581
rs10409541 19 13433127 T C 0.087 0.048
rs11020772 12 70792582 T G 0.001 0.966
rs11145506 9 80264584 T C −0.117 0.282
rs12317962 12 70792582 T G 0.001 0.966
rs12582971 12 18459387 T C −0.001 0.981
rs17629494 10 53560898 T C −0.060 0.217
rs17643974 10 126792798 T C 0.002 0.964
Abbreviations: BP, base pair in HG19; Chr, chromosome; OR, odds ratio; SNP,
single-nucleotide polymorphism. The SNP name, chromosome, base pair,
reference allele, alternate allele, natural log of the odds ratio and P-value
are presented from the meta-analysis of autism spectrum disorders from
the Psychiatric Genomics Consortium. This meta-analytic strategy reﬂects
the weighted combination of the contributing cohorts reﬂective of power
to detect association. None of the SNPs meet a multiple testing
signiﬁcance threshold, let alone the genome-wide association threshold
of 5×10
−8.
Table 2. Pathway results from the PGC meta-analysis of ASDs
KEGG pathway name FORGE INRICH MAGENTA SS ALIGATOR
Purine metabolism 0.715 0.012 0.140 0.477 0.255
Calcium signaling 0.907 0.719 0.828 0.782 0.987
Chemokine signaling
pathway
0.060 0.870 0.614 0.418 0.879
Phosphotidylinositol
signaling
0.256 0.734 0.317 0.480 0.632
Oocyte meiosis 0.986 0.522 0.743 0.771 0.301
Ubiquitin-mediated
proteolysis
0.658 0.429 0.741 0.451 0.943
Wnt signaling 0.863 0.480 0.626 0.408 0.552
Axon guidance 0.611 0.502 0.289 0.083 0.654
Focal adhesion 0.837 0.435 NA 0.685 0.374
Cell adhesion
molecules
0.278 0.472 0.963 0.054 0.255
Gap junction 0.786 0.768 0.780 0.676 0.926
LTM 0.006 0.011 0.078 0.066 0.014
Long-term
potentiation
0.937 0.883 0.961 0.742 0.969
Long-term depression 0.727 0.450 0.643 0.230 0.422
Taste transduction 0.510 1.000 0.900 0.670 0.692
Insulin signaling
pathway
0.455 0.318 0.013 0.693 0.187
GnRH signaling 0.357 0.589 0.658 0.575 0.927
Melanogenesis 0.520 0.496 0.509 0.444 0.660
Abbreviations: ASD, autism spectrum disorder; GWAS, genome-wide
association study; LTM, leukocyte transendothelial migration; NA, not
applicable. Pathway results from the PGC Network and Pathway Analysis
(PGC-NPA) group as applied to the meta-analysis results from PGC Autism.
Five different methods are presented: FORGE, INRICH, MAGENTA, Set
Screen (SS) and ALIGATOR. These methods have been documented
elsewhere
6–10 and represent some of the leading methods for pathway
analysis using GWAS data. None of the pathways identiﬁed in the Skaﬁdas
paper survive a multiple-testing correction based on the PGC ASD meta-
analysis.
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disclosed in Skaﬁdas et al.
1 (their Table 2) for ASDs in the PGC. We
wrote to the authors, asking for the complete list of 237 SNPs and
weights, but they declined to provide the complete list. We
accordingly built a classiﬁer using the data for 30 SNPs disclosed in
Skaﬁdas et al.,
1 which the authors identify as the most inﬂuential
(explaining approximately 58% of the total predictive power of the
classiﬁer). We constructed the classiﬁer using two approaches. We
initially used the weights provided by Skaﬁdas et al.
1 and
examined the predictive ability of the 30 SNP classiﬁer in the
full PGC autism sample. As described in detail in Supplementary
Information, the classiﬁer did not differ from chance in its ability to
predict ASDs (AUC=0.505, P=0.22).
We then built the score using the SNP weights estimated from
the PGC data. We randomly selected a set of 732 trios to build a
classiﬁer and then tested the predictive ability of the classiﬁer in a
distinct set of 243 trios (these number mirror those used by
Skaﬁdas et al.
1). For all trios, we created case pseudo–control pairs
to perform model building and validation, but otherwise followed
the methods proposed in Skaﬁdas et al.
1 (for example, using 0, 1, 3
scoring against minor allele count). We repeated this procedure
across 100 random samples of the same size from the PGC autism
data. Across these replicates, we tested for a difference between
case and control risk scores using a t-test (mean risk score of
cases—mean risk score of controls) and found an average
t-statistic of 0.492 with an average P-value of 0.50 for the
validation samples. We conclude that the classiﬁer presented by
Skaﬁdas et al.,
1 at least as constructed using the 30 top SNPs
named in their report, does not generalize to predict ASDs in other
samples. This result strongly suggests that the Skaﬁdas et al.
1
results cannot be used to predict ASDs.
We repeated the set of analyses above using a case–control
design, to mirror the approach employed by Skaﬁdas et al.
1 We
used 732 cases matched with 732 population controls for
discovery, and 243 cases matched with 243 population controls
for validation, much as the authors initially reported. In these
comparisons, when principal components were included in the
analysis to control for population ancestry, we observed nearly
identical results to what we found in the family-based study
described above (see Supplementary Information). However,
without controlling for population ancestry, we observed a bias
in estimates of the AUC for the curve, suggesting that such bias
may have contributed to the results reported by Skaﬁdas et al.,a s
has already been suggested.
3
Finally, we evaluated the signiﬁcance of the pathways identiﬁed
by Skaﬁdas et al.
1 (their Table 1), the analysis which provided the
basis for their SNP selection. We did not observe signiﬁcant
evidence for a relationship between any of these pathways and
ASDs using ﬁve different pathway analysis tools in the combined
PGC ASD sample set (Table 2). This result strongly suggests that
the pathway analyses do not generalize to external samples and
therefore cannot be validly used in the development of a classiﬁer.
To put the results reported in Skaﬁdas et al.
1 into perspective,
consider the magnitude of effects implied by the results of the
classiﬁer. From the external validation experiment, the authors
report an area under the receiver operating characteristic curve
0.747 (Skaﬁdas et al., Supplementary Figure S2). This result implies
that their SNP-set explains ∼11% of variation in liability to ASDs
(assuming a prevalence of 1% and a liability threshold model).
4
For complex traits, in particular psychiatric disorders, explaining so
much variation with so few SNPs and such a small discovery
sample size (732 cases and 123 controls) is unprecedented, and
inconsistent with results from genome-wide association studies.
For example, to achieve similar levels of variance explained in
human height, sample sizes of ∼180000 individuals were
required.
5
We ﬁnd no evidence that the implicated SNPs, the classiﬁer or
the pathways named in Skaﬁdas et al.
1 are associated with ASDs.
We therefore conclude that the classiﬁer, as presented, cannot be
used in a general way to predict ASDs, and consequently is
unlikely to have any translational value.
The differences between the report of Skaﬁdas et al.
1 and our
analyses are striking. We suspect that our failures to replicate their
claims originate from several issues with the original analyses and
data. In particular, the failure to control for potential population
stratiﬁcation in Skaﬁdas et al.
1 has likely led to biased estimates of
allelic effects, as suggested in a recent letter.
3 We detail other
technical issues in Supplementary Information, which may also
explain the differences in the results.
There are a great many challenges to the accurate interpreta-
tion of genomic data and multiple false-positive associations from
technical or study design biases have been identiﬁed in the
literature. We conclude that the classiﬁer presented in Skaﬁdas
et al.
1 will not usefully identify individuals at risk for ASDs in the
population. Nevertheless, there are increasing numbers of robust
and replicable ﬁnding emerging in psychiatric genetics. These
ﬁndings hold great promise for understanding the biological basis
of psychiatric disorders and for translation.
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